Today, THCA Therapeutics had the opportunity to present its long-term vision and scientific strategy to High-Tech Gründerfonds (HTGF), one of Germany’s leading early-stage investors focused on deep technology and life sciences.

The discussion introduced our THCA PURE platform, our strategy for developing non-intoxicating cannabinoid therapeutics, and our long-term roadmap toward pharmaceutical development.

While this meeting represents an early step in our journey, it reflects our commitment to actively engaging with Germany’s biotechnology ecosystem and building relationships with organizations that support scientific innovation.

Status

• ✓ Company Presentation
• ✓ Strategic Introduction
• ✓ Investor Dialogue
• → Ongoing Relationship